On September 25, 2018, in a letter to members of Congress, the Department of Justice reaffirmed its longstanding policy that Title III of the Americans with Disabilities Act (ADA) applies to websites, though once again, it declined to issue specific regulations on what websites need to do to comply with the law.
The ongoing lack of clarity has resulted in thousands of lawsuits being filed against American companies for their websites’ purported noncompliance with Title III. The uncertainty provides more impetus to design with accessibility in mind, a goal that also provides benefits to patients with disabling conditions and comorbidities, as well as the public at large. An accessibility review can be a great first step toward determining your best course of action.
In this POV, Intouch user experience expert Amy Toft explains the importance of accessibility, how adherence to Title III affects websites, and how making content accessible to all users affects pharma.